reports
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufa...
Lonza Group AG / Key word(s): Expansion Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of manufacturing space will include two additional production suites and supporting infrastructure A significant increase in bioconjugation capacity will enable Lonza to offer expertise to a broad customer base and address the expected increase in approvals Basel, S...
Lonza Extends Collaboration with Major Pharmaceutical Partner for Inte...
Lonza Group AG / Key word(s): Partnership/Agreement Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates 22.10.2024 / 07:00 CET/CEST Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds on a successful long-term collaboration and strong track record of manufacturing all key elements of bioconjugates at commercial scale Basel, Switzerland, 22 October 2024 – Lonza, a gl...
Lonza Nominates David Meline as Independent Board Member
Lonza Group AG / Key word(s): Personnel Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting Basel, Switzerland, 3 October 2024 - Today, Lonza’s Board of Directors announced the nomination of David Meline as an Independent Member of the Board. The Board will propose the election of David to shareholders at the Lonza Group Annual General Meeting (AGM) in May 20...
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville...
Lonza Group AG / Key word(s): Acquisition Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network Additional large-scale capacity enables Lonza to harness sustained demand for commercial manufacturing, and to continue supporting a strong pipeline of molecules on the path to market B...
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASG...
Lonza Group AG / Key word(s): Partnership Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell therapy manufacturing facility with plans to expand to Portsmouth, NH (US) Geleen (NL) site is now approved by the FDA, EMA and MHRA for the commercial production of CASGEVY® Basel, Switzerland, 24 September 2024 – Lonza, a global manufac...
- Dominic Rose
- Naresh Chouhan
Lonza - D/G to HOLD – Risk From Higher Yields (HOLD [BUY], TP CHF 550 ...
Our deep dive into biologic manufacturing yields [HERE] has led to our questioning the wisdom of Lonza’s huge Vacaville deal, given that it uses 12kL & 25kL fed batch bioreactors, while the sector is increasingly turning to higher yielding novel technologies. 70% of Vacaville is empty, with the 30% contracted by Roche phasing out over time. If Lonza cannot sign new contracts to fill this 330kL facility, it will slow growth and create a material margin headwind for the foreseeable future, imperil...
- Dominic Rose
- Naresh Chouhan
Global Bioprocessing - 5% Mid-Term Trend Growth (12pgs)
We show clear evidence that rapidly improved yields are the missing link in the mystery of the Bioprocessing slowdown. New analysis using our proprietary biologic demand model shows that industry trend growth could have fallen to just 5% & higher yields explain the slow recovery & poor visibility. We believe trend growth is now MSD 2024-26, at best. We will attend the biggest Bioprocessing trade conference next week to better understand complex industry trends & the feasibility of rapid yield im...
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
Lonza Group AG / Key word(s): Bond Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds 28.08.2024 / 18:31 CET/CEST Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds. The bonds have a maturity of six and ten years with coupons of 3.25% and 3.50% respectively.The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the Luxembourg Stock Exchange ...
Lonza Group AG: 1 director
A director at Lonza Group AG sold 395 shares at 581.440CHF and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Jerôme Bodin
FP TOTAL SE
AC ACCOR SA
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
JMT JERONIMO MARTINS SGPS S.A.
CA CARREFOUR SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ROG ROCHE HOLDING LTD
SK SEB SA
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
CPG COMPASS GROUP PLC
NESN NESTLE S.A.
VIV VIVENDI SE
NRG NRJ GROUP SA
RF EURAZEO SA
KER KERING SA
ELE ENDESA S.A.
SAN SANOFI
VER VERBUND AG CLASS A
EZJ EASYJET PLC
REP REPSOL SA
SOI SOITEC SA
SIX2 SIXT SE
MOCORP METSO OUTOTEC OYJ
MONC MONCLER SPA
IBE IBERDROLA SA
AZN BANCO SANTANDER S.A.
VOD ASTRAZENECA PLC
STM VODAFONE GROUP PLC
BESI STMICROELECTRONICS NV
ULA BE SEMICONDUCTOR INDUSTRIES N.V.
ERF UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
STLA EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
UMG STELLANTIS N.V.
DSY UNIVERSAL MUSIC GROUP NV
ML DASSAULT SYSTEMES SA
GSK COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 GSK PLC
SGSN DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
NOVO B SGS SA
NOVO NORDISK A/S
- Jerôme Bodin
FP TOTAL SE
AC ACCOR SA
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
JMT JERONIMO MARTINS SGPS S.A.
CA CARREFOUR SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ROG ROCHE HOLDING LTD
SK SEB SA
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
CPG COMPASS GROUP PLC
NESN NESTLE S.A.
VIV VIVENDI SE
NRG NRJ GROUP SA
RF EURAZEO SA
KER KERING SA
ELE ENDESA S.A.
VER SANOFI
EZJ VERBUND AG CLASS A
REP EASYJET PLC
SOI REPSOL SA
SIX2 SOITEC SA
MOCORP SIXT SE
MONC METSO OUTOTEC OYJ
IBE MONCLER SPA
SAN IBERDROLA SA
AZN BANCO SANTANDER S.A.
VOD ASTRAZENECA PLC
STM VODAFONE GROUP PLC
BESI STMICROELECTRONICS NV
ULA BE SEMICONDUCTOR INDUSTRIES N.V.
ERF UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
STLA EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
UMG STELLANTIS N.V.
DSY UNIVERSAL MUSIC GROUP NV
ML DASSAULT SYSTEMES SA
GSK COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 GSK PLC
SGSN DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
NOVO B SGS SA
NOVO NORDISK A/S
- Oliver Metzger
- Stephan Wulf
Lonza : Strong H1 results driven by Biologics
>A set of strong H1 results - Lonza reported a set of strong H1 2024 results. Group sales came in at CHF 3,057m (-0.7% and +1.8% at CER), slightly below our estimates (CHF 3,105m) but above the consensus (CHF 3,015m). Core EBITDA is at CHF 893m (-3.1%; +0.6% at CER) beating our estimates (CHF 853m) by 5% and cons. (CHF 802m) by 11%. The y-o-y decline reflects the loss of Covid-related mRNA business. The shortfall at the net earnings level (CHF 330m vs our estimates of...
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Member...
Lonza Group AG / Key word(s): Personnel Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members 25.07.2024 / 07:00 CET/CEST Basel, Switzerland, 25 July 2024 - Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 2025. This announcement follows a which reported measures to improve Board governance, succession planning and focus on organizational health. Building on these...
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
Lonza Group AG / Key word(s): Personnel Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand 01.07.2024 / 07:00 CET/CEST Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group Albert M. Baehny will retire from Lonza Group following a transition period Basel, Switzerland, 1 July 2024 – Wolfgang Wienand joins Lonza Group today as Chief Executive Officer (CEO). Wolfgang succeeds Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of Directors of Lonza from 2018 to May 2024. Albert will work with ...
Lonza gibt Ergebnisse der Generalversammlung 2024 bekannt – Alle Anträ...
Lonza Group AG / Schlagwort(e): Generalversammlung Lonza gibt Ergebnisse der Generalversammlung 2024 bekannt – Alle Anträge des Verwaltungsrats wurden genehmigt 08.05.2024 / 15:00 CET/CEST Jean-Marc Huët wurde als Präsident des Verwaltungsrats gewählt Die Aktionäre wählten alle zur Wiederwahl stehenden Verwaltungsratsmitglieder wieder Eine Dividende von CHF 4.00 pro Aktie wird ab dem 15. Mai 2024 ausgeschüttet Die anwesenden und vertretenen Aktionäre hielten insgesamt 29'994'055 Aktien, was 40.28% des Aktienkapitals entspricht Deloitte wurde als Revisionsstelle für das Geschäft...
Lonza Announces Results of the 2024 Annual General Meeting – All Motio...
Lonza Group AG / Key word(s): AGMEGM Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved 08.05.2024 / 15:00 CET/CEST Jean-Marc Huët was elected as Chairman of the Board of Directors Shareholders re-elected all members of the Board of Directors standing for re-election A dividend of CHF 4.00 per share will be paid out starting from 15 May 2024 Attending and represented shareholders collectively held a total of 29,994,055 shares, representing 40.28% of the share capital Deloitte has been re-elected as auditor for finan...
- Martin Marandon-Carlhian
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Martin Marandon-Carlhian
- Stephane Houri
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Oliver Metzger
- Stephan Wulf
Lonza : Lonza has improved its strategic position in biologics and is ...
>Lonza’s equity story has become more attractive since our initiation - Since we initiated the coverage of Lonza on 5 March 2024, several aspects of the equity story have further improved. The appointment of Wolfgang Wienand as CEO in April has ended a period of uncertainty regarding the company's future leadership. Even more importantly, Lonza's strategic position has improved with the acquisition of Genentech in the US. This is particularly true regarding the expect...
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Group AG / Key word(s): Bond/Financing Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon 17.04.2024 / 19:00 CET/CEST Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion straight bond. The Eurobond marks Lonza’s second drawdown under its EMTN program. The bond has a maturity of 12 years and an annual coupon of 3.875%. The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.